PFBT
RETA

Parkside Financial Bank & Trust’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Parkside Financial Bank & Trust’s Portfolio RETA Stock Details RETA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-9
Closed -$1K – 1950
2021
Q3 		$1K Sell
9
-2
-18% -$234 ﹤0.01% 1737
2021
Q2 		$2K Buy
+11
New +$1.24K ﹤0.01% 1594

Other funds holding RETA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Parkside Financial Bank & Trust's RETA Position: Q4 2021 in Review

Parkside Financial Bank & Trust sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q4 2021, closing a stake of 9 shares — an estimated $1K sold.

Parkside Financial Bank & Trust first reported a position in RETA in Q2 2021 and held it in 2 quarters. The position peaked at $2K in Q2 2021. 151 funds tracked by Wall St. Rank hold RETA as of Q4 2021.

  • Parkside Financial Bank & Trust reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q4 2021 after selling out during the quarter.
  • Parkside Financial Bank & Trust sold 9 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q4 2021, an estimated $1K.
  • Parkside Financial Bank & Trust first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2021 and held it in 2 quarters.
  • Parkside Financial Bank & Trust's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $2K in Q2 2021.
  • 151 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q4 2021.

Based on Parkside Financial Bank & Trust's 13F filing for Q4 2021, filed 14 Feb 2022.